Conditioning of LMVECs with SSc serum resulted in a significant reduction of VEGFR3/FLT4 and NRP2 mRNA levels, determined by quantitative real-time PCR (p < 0.001 vs. healthy serum-treated LMVECs for both) (Figure 5). The gene discussed is FLT4; the disease is systemic sclerosis.